vimarsana.com

Page 5 - போஹெரிங்கர் இஂகல்‌ஹைம் மருந்துகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Post-baccalaureate Program Focuses on Lung Disease Research

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial | Diabetes | JAMA

Researchers create cellular blueprint of healthy lungs

By Bill Hathaway May 25, 2021 Share this with FacebookShare this with TwitterShare this with LinkedInShare this with EmailPrint this (Illustration by Michael S. Helfenbein) The primary function of the lung is to facilitate transfer of oxygen to the blood stream. Crucial to this lifegiving task are endothelial cells, which line blood vessels permeating the lung and through which gas exchange occurs. Malfunction of these cells is implicated in a range of different diseases, including COPD (chronic obstructive pulmonary disease), pulmonary fibrosis, and pulmonary hypertension. And the COVID-19 pandemic has raised important questions about these cells: Why are some endothelium cells, particularly in the elderly, more susceptible to injury from the disease?

Researchers create cellular blue print of healthy lungs

VOLTAIRE-X phase III data in patients with moderate-to-severe chronic plaque psoriasis support interchangeability application

Share this article Share this article RIDGEFIELD, Conn., April 23, 2021 /PRNewswire/  Boehringer Ingelheim today announced results from a phase III, randomized study that concluded that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate-to-severe chronic plaque psoriasis. The 32-week data will be presented at the American Academy of Dermatology 2021 virtual meeting experience. We are proud to present the results from Voltaire-X, a landmark study that supports Boehringer Ingelheim s application for interchangeability between Cyltezo® and Humira®, said Thomas Seck, Senior Vice President, Medicine and Regulatory Affairs at Boehringer Ingelheim. This first-of-its-kind switching study further reinforces our goal to broaden access to biosimilar treatment options while contributing to the quality and sustainability of healt

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.